PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full approval, sending the drugmaker's shares soaring and easing concerns around the ...

CEO Frank Bedu-Addo highlighted the initiation of the VERSATILE 003 Phase 3 clinical trial of Versamune HPV plus pembrolizumab for first-line recurrence and/or metastatic HPV16-positive head and neck ...

Discover Agenus Inc.'s Q1 2025 highlights, including groundbreaking BOT/BAL data, strategic transactions, financial updates, and insights on ...

Mayank Mamtani, B. Riley Securities: Asked about BARDA correspondence, sentinel cohort learnings, and norovirus DSMB review. CMO Cummings noted, "we intend to engage with our partners at BARDA to ...

Mayank Mamtani, B. Riley Securities: Inquired about the R&D pipeline and potential IND filings. Draghia-Akli stated that early-stage programs are in preclinical phases, with data expected in the ...

Explore Novavax's Q1 2025 earnings insights, highlighting raised revenue forecasts, strategic partnerships, and progress toward non-GAAP profitability ...

Mayank Mamtani, B. Riley Securities, asked about development plan changes post-AACR update and focus beyond CRC. Dr. Goldberg stated, "the shortest distance between presentation and approval is in ...

Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow ...